Becoming a sponsor or exhibitor
Exploratory Clinical Development World Americas will bring together leaders, decision makers and influencers in early clinical research & development. Our delegates will be looking for guidance, answers and new business relationships, representing a significant and exceptional business opportunity. As a CRO, laboratory or technology provider, this conference represents an exceptional opportunity to develop new business relationships.
The event offers a variety of conference and networking formats including; workshops, seminars, plenary sessions, streamed sessions, breakfast briefing, speed networking, online contact system and a sociable drinks reception. All social events will take place in the exhibition area, giving you maximum opportunity to mix with the attendees.
As a sponsor of this event you will be able to select a sponsorship package that is best suited to your marketing objectives and your preferred communication style. By sponsoring or exhibiting at this event you will:
- Uncover new opportunities and generate leads
- Gain access to your target market
- Integrate with the early clinical and phase one community
- Enhance your brand and market position
- Showcase your products and services
Questions to determine your involvement; do you offer services and solutions that support the challenges of early clinical development? Could you benefit from introductions to and time with early phase decision makers? Is it cost & time effective to meet multiple prospects & clients in one setting?
Sponsorship opportunities can be tailored to your specific objectives and marketing requirements, let us know what you want to achieve and we will develop a promotional solution with you.
To learn more about the sponsorship and exhibition opportunities please contact Claire Conway on Tel: +44 (0) 207 608 7058 or email cconway@healthnetworkcommunications.com
Meet our sponsors...
|
Quotient Bioresearch
|
|
 Quotient Clinical is a strategic business unit of Quotient Bioresearch. We have a strong heritage of expertise in early clinical development studies from First-in-Human through to Proof-of-Concept, augmented by our unique capabilities in drug product optimisation and 14C enabled drug development.
Working closely with pharmaceutical and biotechnology partners worldwide we build and perform comprehensive development programmes enabling our partners to:
• select candidate drugs with the greatest potential for success
• understand fully the development potential of new drug candidates
• Identify, manufacture and test the most appropriate formulations and drug delivery options
• Understand the issues affecting therapeutic drug levels in the body
• Evaluate and identify the most appropriate options for life cycle management
• Overcome the need for extensive stability data via extemporaneous manufacture
• Use flexible clinical protocols allowing real-time evaluation of clinical data to drive decision making
Quotient Clinical is at the forefront of innovative drug development using integrated study designs that provide invaluable information on multiple aspects of drug development in a single study, reducing the need for additional trials and substantially reducing time and cost.
www.quotientbioresearch.com
|
|
Vince & Associates Clinical Research
|
|
 Dr. Vince has been conducting clinical trials for over a decade and has to-date participated as an investigator in well over 300 clinical trials in all phases of development. His primary focus is early development from Phase 1 to Proof-of-Concept. He is intricately involved in all aspects of the clinical trial process from protocol development to recruitment. Furthermore, Dr. Vince has significant knowledge in recruitment of special populations for early development trials from pediatric, elderly and other disease-state populations.
Dr. Vince serves as President and Medical Director of Vince & Associates Clinical Research, Inc. Vince & Associates is comprised of three facilities that make up the Vince & Associates Clinical Research campus in Overland Park, KS - An 80-bed Phase I CPU, a 12,000 square foot dedicated Outpatient Research Facility and a 12-bed accredited Sleep Research Center. Having served over 90 pharma/biotech clients since its inception, Vince & Associates Clinical Research is well known and respected for its rapid study start-up, impressive recruitment and retention of research volunteers and superior data quality.
www.vinceandassociates.com.
|
|
iCardiac
|
|
 iCardiac Technonogies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry’s most sophisticated FDA-accepted cardiac safety assessment methodologies.
iCardiac’s analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including our Highly Automated QT(sm), which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies.
In addition, iCardiac provides Beyond QT(sm), a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development.
iCardiac’s COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. iCardiac’s scientific and medical staff work with the FDA’s IRT team as external experts on improving standards for cardiac safety testing in clinical development.
www.icardiac.com
|
|
PRA International
|
|
 PRA's Early Development Services (EDS) group provides comprehensive services for Phase I and Phase IIa clinical research, bioanalytical research and data support. Our expertise is primarily with more complex types of studies in which safety and intelligent design are critical factors. PRA EDS conducts more than 100 complex Phase I and IIa studies and over 200 bioanalytical studies yearly for studies recruiting healthy volunteers or special patient populations.
Through harmonized clinical and laboratory facilities in The Netherlands, the United States, and Central and Eastern Europe, PRA EDS offers over 220 beds worldwide. Each Clinical Pharmacology Unit is equipped with the technologies and infrastructure needed for high quality, efficient studies on a wide range of drugs and indications. PRA EDS has developed extensive methodologies enabling us to conduct studies with delicate pharmacokinetic and/or pharmacodynamic objectives.
PRA International is one of the world's leading global clinical research organizations, conducting clinical trials in more than 60 countries across six continents. PRA provides outsourced clinical services across all phases of pharmaceutical and biotech drug development. Through its 30+ years of experience, PRA has developed the operational and therapeutic expertise to provide high quality, global service while maintaining our differentiating PERSONAL ELEMENT of commitment to excellence.
www.pra.com
|
|
Nadine Cohen
Mitchell B. Friedman
Malcolm Mitchell
Dr Russell Weiner
